Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study

[1]  Pratik Sinha,et al.  Is a "Cytokine Storm" Relevant to COVID-19? , 2020, JAMA internal medicine.

[2]  M. Nishimura,et al.  Save the ICU and save lives during the COVID-19 pandemic , 2020, Journal of Intensive Care.

[3]  N. Thakur,et al.  Management and Outcomes of Critically-III Patients with COVID-19 Pneumonia at a Safety-net Hospital in San Francisco, a Region with Early Public Health Interventions: A Case Series , 2020, medRxiv.

[4]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[5]  R. Claus,et al.  Postmortem Examination of Patients With COVID-19. , 2020, JAMA.

[6]  W. Wang,et al.  Viral and host factors related to the clinical outcome of COVID-19 , 2020, Nature.

[7]  D. Wright.  Prevention of the cytokine storm in COVID-19 , 2020, The Lancet Infectious Diseases.

[8]  Amber Dance.  What is a cytokine storm? , 2020 .

[9]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[10]  T. West,et al.  Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England Journal of Medicine.

[11]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[12]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[13]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[14]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[15]  K. Delucchi,et al.  Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. , 2020, The Lancet. Respiratory medicine.

[16]  C. Calfee,et al.  Phenotypes in acute respiratory distress syndrome: moving towards precision medicine , 2019, Current opinion in critical care.

[17]  Kevin L. Delucchi,et al.  Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study , 2018, Intensive Care Medicine.

[18]  J. Laffey,et al.  Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. , 2018, The Lancet. Respiratory medicine.

[19]  V. Sapin,et al.  Recent directions in personalised acute respiratory distress syndrome medicine. , 2017, Anaesthesia, critical care & pain medicine.

[20]  K. Famous,et al.  Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy , 2016, American journal of respiratory and critical care medicine.

[21]  G. Bernard,et al.  Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. , 2014, Chest.

[22]  G. Perkins,et al.  Simvastatin in the acute respiratory distress syndrome. , 2014, The New England journal of medicine.

[23]  Kevin Delucchi,et al.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[24]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[25]  G. Rubenfeld,et al.  Causes and timing of death in patients with ARDS. , 2005, Chest.